Filing Details

Accession Number:
0001209191-19-030723
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-05-17 11:47:11
Reporting Period:
2019-05-15
Accepted Time:
2019-05-17 11:47:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1662395 Douglas Jason Wilson 2801 Gateway Drive
Suite 150
Irving TX 75063
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2019-05-15 4,000 $0.00 4,000 No 4 C Direct
Class A Common Stock Disposition 2019-05-15 900 $88.74 3,100 No 4 S Direct
Class A Common Stock Disposition 2019-05-15 1,600 $89.82 1,500 No 4 S Direct
Class A Common Stock Disposition 2019-05-15 1,500 $90.70 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Employee Stock Option (right to buy) Disposition 2019-05-15 4,000 $0.00 4,000 $11.00
Class A Common Stock Class B common stock Acquisiton 2019-05-15 4,000 $11.00 4,000 $0.00
Class A Common Stock Class B common stock Disposition 2019-05-15 4,000 $0.00 4,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
66,881 2026-05-25 No 4 M Direct
47,646 No 4 M Direct
43,646 No 4 C Direct
Footnotes
  1. The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018.
  2. The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $88.26 to $89.16. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $89.32 to $90.22. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $90.35 to $90.87. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  6. The options, representing a right to purchase a total of 101,881 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016.